Results

Total Results: 1,455 records

Showing results for "analyzed".

1. Appendix-E-Evidence-Tables-E1-E4 0 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/Appendix-E-Evidence-Tables-E1-E4_0.xlsx
   November 04, 2021 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

2. Cannabis-2022-Surv-Rep-3-Tables-F1-4 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-tables-F1-4.xlsx
   January 01, 2022 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

3. App-E-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
   September 20, 2022 - Trial Type Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed

4. Cannabis-2022-Update-Surv-Rep-1-App-F1-4 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
   January 01, 2022 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

5. Cannabis-App-F1-F4-Tables-Surveillance-Report-2 0 0 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-app-f1-f4-tables-surveillance-report-2_0_0.xlsx
   February 16, 2022 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

6. Cer-250-Cannabis-Tables-E1-E4-2022-Update 0 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-e1-e4-2022-update_0.xlsx
   January 01, 2022 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

7. Cannabis-2023-Surv-Rep-1-App-F (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
   January 01, 2023 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

8. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
   January 01, 2023 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

9. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
   January 01, 2022 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

10. Cer-250-Cannabis-2024-Surv-Rep-Update-Tables-E1-4 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-tables-e1-4.xlsx
    January 01, 2024 - for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed … for Between Group Mean ∆ Intervention B, N Analyzed for Between Group Mean ∆ Intervention C, N Analyzed

11. App-E-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Trial Type Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed

12. App-E-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Trial Type Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed … Trial Name Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized N Analyzed

13. App-D-Opioid-Chronic-Pain-Surveillance-Report-2 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-2.xlsx
    September 30, 2015 - Setting Country Eligibility Criteria Interventions Sample Characteristics Screened Eligible Randomized Analyzed … B Screened: 88 Eligible: 30 Randomized: 30 Analyzed: 27 A vs. … Urine + for opiates: 63% Self-reported use of opiates: 89% Screened: 65 Eligible: 25 Randomized: 19 Analyzed … B Screened: 68 Eligible: 53 Randomized: 46 Analyzed: 40 (20 vs. 20) A vs. … Comparison Groups Population Characteristics Method for Assessing Outcomes and Confounders Enrolled Analyzed

14. App-D-Opioid-Chronic-Pain-Surveill-Report-1 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
    September 30, 2015 - Setting Country Eligibility Criteria Interventions Sample Characteristics Screened Eligible Randomized Analyzed … B Screened: 88 Eligible: 30 Randomized: 30 Analyzed: 27 A vs. … Urine + for opiates: 63% Self-reported use of opiates: 89% Screened: 65 Eligible: 25 Randomized: 19 Analyzed … B Screened: 68 Eligible: 53 Randomized: 46 Analyzed: 40 (20 vs. 20) A vs. … Comparison Groups Population Characteristics Method for Assessing Outcomes and Confounders Enrolled Analyzed

15. App-D-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
    September 30, 2015 - Setting Country Eligibility Criteria Interventions Sample Characteristics Screened Eligible Randomized Analyzed … B Screened: 88 Eligible: 30 Randomized: 30 Analyzed: 27 A vs. … B Screened: 113 Eligible: 110 Randomized: 110 Analyzed: 110 (55 vs. 55) A vs. … B Screened: 1,669 Eligible: NR Randomized: 301 Analyzed: 293 A vs. … B Screened: 68 Eligible: 53 Randomized: 46 Analyzed: 40 (20 vs. 20) A vs.

16. Cancer-Anemia-Update Executive (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cancer-anemia-update_executive.pdf
    April 01, 2013 - Conclusions Evidence from three groups of trials were summarized and analyzed for Key Question 1. … Control Number of trials 5 31 7 38 Patients analyzed 2,005 8,003 2,806 10,809 Pooled RR (95% CI) 1.14 … Control Number of trials 37 7 44 Patients analyzed 11,131 3,147 14,278 Pooled HR (95% CI) 1.04a 1.04 … Control Number of trials 14 Patients analyzed 3,643 Mean difference for change in FACT-Fatigue score … Early Versus Late ESA Treatment Evidence from five trials was summarized and analyzed; 468 and 465

17. Empirical and Simulation-Based Comparison of Univariate and Multivariate Meta-Analysis for Binary Outcomes | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/methods-binary-outcomes-evaluation/research
    November 01, 2017 - They can be approached with separate, independent meta-analyses, or they can be analyzed jointly, in … first quarter) to identify sets of univariate meta-analyses of categorical outcomes that can also be analyzed … We analyzed these data with univariate and multivariate meta-analysis.

18. App-D-Surv-Report-3-Noninvasive-Nonpharma 0 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - Randomized: 126 Analyzed: 126 Attrition: 7.9% (10/126) A. … Randomized: 70 Analyzed: 70 Attrition: 50% (35/70) A. … at 26 weeks: 251 Analyzed at 52 weeks: 258 A. … Randomized: 51 Analyzed: 47 Attrition: 8% (4/51) A. … Randomized: 39 Analyzed: 39 Attrition: 0% (0/37) A.

19. Association of Digestible Carbohydrate Intake With Cardiovascular Disease, Type 2 Diabetes, Obesity, and Body Composition | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/effect-dietary-digestible/research
    March 01, 2025 - When digestible carbohydrate intake was analyzed as the percentage of total energy intake, the risk of … When digestible carbohydrate intake was analyzed as grams per day, the risk of CVD significantly increased … When carbohydrate intake was analyzed as the percentage of total energy intake, the risk of incident … When carbohydrate intake was analyzed as grams per day, the risk of incident cardiovascular disease significantly

20. App-D-Surv-Report-2-Noninvasive-Nonpharma (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
    January 01, 2021 - Randomized: 126 Analyzed: 126 Attrition: 7.9% (10/126) A. … Randomized: 59 Analyzed: 50 Attrition: 15.2% (9/59) A. … Randomized: 70 Analyzed: 70 Attrition: 50% (35/70) A. … at 26 weeks: 251 Analyzed at 52 weeks: 258 A. … Randomized: 51 Analyzed: 47 Attrition: 8% (4/51) A.